References for cell isolation with MHC I Streptamers®

Streptamer® Technology: Magnetic MHC I Streptamers®
  1. Schlott F.; Steubl D.; Ameres S.; Moosmann A.; Dreher S.; Heemann U.; Hösel V.; Busch D.H. and Neuenhahn M. (2018) Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8+ T cells. PLOS ONE13(2): e0193554.[Link]

  2. Odendahl, M.; Grigoleit, G.U.; Bönig, H.; Neuenhahn, M.; Albrecht, J.; Anderl, F.; Germeroth, L.; Schmitz, M.; Bornhäuser, M.; Einsele, H.; Seifried, E.; Busch, D. H. and Tonn, T. (2014) Clinical-scale isolation of ‘minimally manipulated’ cytomegalovirusspecific donor lymphocytes for the treatment of refractory cytomegalovirus disease. Cytotherapy16 (9), 1245-1256 [Link]

  3. Wang, X-C., Pang, H., Schmitt, A., Freund, M., Schmitt, M. and Chen B.-A. (2013) Streptamer versus tetramer-based selection of functional cytomegalovirus-specific T cells. Journal of the Formosan Medical Association112: 338-354 [Link]

  4. Wang, X., Schmitt, A., Chen, B., Xu, X., Mani, J., Linnebacher, M., Freund, M. and Schmitt, M. (2010) Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions. Experimental Hematology 38, 1066-1073. [Link]

Streptamer® Technology: Purity and Yield with MHC I Streptamers®
  1. Roex M.C.J.; Hagemann L.; Heemskerk M.T.; Veld S.A.J.; van Liempt E.; Kester M.G.D.; Germeroth L.; Stemberger C.; Falkenburg J.H.F. and Jedema I. (2018) The simultaneous isolation of multiple high and low frequent T-cell populations from donor peripheral blood mononuclear cells using the major histocompatibility complex I-Streptamer isolation technology. Cytotherapy 20: 543-555 [Link]
  2. Keldermann, S.; Heemskerk, B.; Fanchi, L.; Philips, D.; Toebes, M.; Kvistborg, P.; van Buren, M.M.; van Rooij, N.; Michels, S.; Germeroth, L.; Haanen, J.B.A.G. and Schumacher N.M. (2016) Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. Eur. J. Immunology 46: 1351-1360 [Link]
  3. Odendahl, M.; Grigoleit, G.U.; Bönig, H.; Neuenhahn, M.; Albrecht, J.; Anderl, F.; Germeroth, L.; Schmitz, M.; Bornhäuser, M.; Einsele, H.; Seifried, E.; Busch, D. H. and Tonn, T. (2014) Clinical-scale isolation of ‘minimally manipulated’ cytomegalovirusspecific donor lymphocytes for the treatment of refractory cytomegalovirus disease. Cytotherapy 16 (9), 1245-1256 [Link]
  4. Schober, K. and Busch D.H. (2016) TIL 2.0: More effective and predictive T-cell products by enrichment for defined antigen specificities. European Journal of Immunology 46: 1335-1339 [Link]
  5. Wang, X-C., Pang, H., Schmitt, A., Freund, M., Schmitt, M. and Chen B.-A. (2013) Streptamer versus tetramer-based selection of functional cytomegalovirus-specific T cells. Journal of the Formosan Medical Association112: 338-354 [Link]